[{"id":"1da2b0c6-165f-4d0a-a3e8-ec861405f022","acronym":"BGB-3111-402","url":"https://clinicaltrials.gov/study/NCT05640102","created_at":"2022-12-07T16:57:49.810Z","updated_at":"2025-02-25T17:02:16.646Z","phase":"","brief_title":"Observational Study Evaluating the Efficacy and Safety of Zanubrutinib in Participants With Waldenström Macroglobulinemia","source_id_and_acronym":"NCT05640102 - BGB-3111-402","lead_sponsor":"BeiGene","biomarkers":" MYD88","pipe":" | ","alterations":" MYD88 mutation • MYD88 L265P • MYD88 wild-type","tags":["MYD88"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MYD88 mutation • MYD88 L265P • MYD88 wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Brukinsa (zanubrutinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 111","initiation":"Initiation: 03/03/2023","start_date":" 03/03/2023","primary_txt":" Primary completion: 12/01/2026","primary_completion_date":" 12/01/2026","study_txt":" Completion: 12/01/2027","study_completion_date":" 12/01/2027","last_update_posted":"2025-02-03"},{"id":"50186f31-5ca5-4488-bd84-bf563991c783","acronym":"","url":"https://clinicaltrials.gov/study/NCT04438005","created_at":"2021-01-18T21:21:51.408Z","updated_at":"2024-07-02T16:35:04.228Z","phase":"Phase 2","brief_title":"A Study of ICP-022 in Patients With R/R DLBCL","source_id_and_acronym":"NCT04438005","lead_sponsor":"Beijing InnoCare Pharma Tech Co., Ltd.","biomarkers":" MYD88 • CD79B","pipe":" | ","alterations":" MYD88 L265P","tags":["MYD88 • CD79B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MYD88 L265P"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Inokai (orelabrutinib)"],"overall_status":"Completed","enrollment":" Enrollment 3","initiation":"Initiation: 05/07/2020","start_date":" 05/07/2020","primary_txt":" Primary completion: 11/05/2021","primary_completion_date":" 11/05/2021","study_txt":" Completion: 12/13/2021","study_completion_date":" 12/13/2021","last_update_posted":"2024-05-13"},{"id":"15d7a52b-337d-4b37-8862-81c425e8dbd7","acronym":"WAL-KU","url":"https://clinicaltrials.gov/study/NCT02640287","created_at":"2021-01-18T12:50:33.419Z","updated_at":"2024-07-02T16:36:26.833Z","phase":"","brief_title":"Expression of Ku70/XRCC6 in Waldenström's Macroglobulinemia","source_id_and_acronym":"NCT02640287 - WAL-KU","lead_sponsor":"Central Hospital, Nancy, France","biomarkers":" MYD88","pipe":" | ","alterations":" MYD88 mutation • MYD88 L265P","tags":["MYD88"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MYD88 mutation • MYD88 L265P"],"overall_status":"Completed","enrollment":" Enrollment 55","initiation":"Initiation: 02/01/2016","start_date":" 02/01/2016","primary_txt":" Primary completion: 06/01/2020","primary_completion_date":" 06/01/2020","study_txt":" Completion: 07/01/2020","study_completion_date":" 07/01/2020","last_update_posted":"2021-08-06"},{"id":"562ebd23-82cd-46f6-9ef4-7d25eaa6ea36","acronym":"","url":"https://clinicaltrials.gov/study/NCT02400437","created_at":"2021-01-18T11:27:12.209Z","updated_at":"2025-02-25T14:57:11.344Z","phase":"Phase 2","brief_title":"Trial of Ixazomib, Dexamethasone and Rituximab in Patients With Untreated Waldenstrom's Macroglobulinemia","source_id_and_acronym":"NCT02400437","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" MYD88 • CXCR4","pipe":" | ","alterations":" MYD88 L265P • CXCR4 mutation","tags":["MYD88 • CXCR4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MYD88 L265P • CXCR4 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • Ninlaro (ixazomib)"],"overall_status":"Completed","enrollment":" Enrollment 26","initiation":"Initiation: 04/01/2015","start_date":" 04/01/2015","primary_txt":" Primary completion: 11/01/2019","primary_completion_date":" 11/01/2019","study_txt":" Completion: 11/01/2019","study_completion_date":" 11/01/2019","last_update_posted":"2020-09-02"},{"id":"29c8844b-f23b-467c-9e51-a60fcb29db0d","acronym":"DigiWAL","url":"https://clinicaltrials.gov/study/NCT03952052","created_at":"2021-01-18T19:27:05.119Z","updated_at":"2024-07-02T16:36:42.594Z","phase":"","brief_title":"Detection of Recurrent Mutations in Waldenström's Disease","source_id_and_acronym":"NCT03952052 - DigiWAL","lead_sponsor":"Centre Henri Becquerel","biomarkers":" MYD88","pipe":" | ","alterations":" MYD88 L265P","tags":["MYD88"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MYD88 L265P"],"overall_status":"Unknown status","enrollment":" Enrollment 40","initiation":"Initiation: 01/14/2019","start_date":" 01/14/2019","primary_txt":" Primary completion: 01/01/2021","primary_completion_date":" 01/01/2021","study_txt":" Completion: 01/01/2022","study_completion_date":" 01/01/2022","last_update_posted":"2020-07-30"},{"id":"4e3f0ddf-4f8e-474d-aded-a7678e71df1c","acronym":"","url":"https://clinicaltrials.gov/study/NCT02252146","created_at":"2021-01-18T10:34:26.083Z","updated_at":"2024-07-02T16:37:15.602Z","phase":"Phase 1/2","brief_title":"Dose Escalation Study in Patients With Relapsed or Refractory DLBCL and MyD88 L265P Mutation","source_id_and_acronym":"NCT02252146","lead_sponsor":"Idera Pharmaceuticals, Inc.","biomarkers":" MYD88","pipe":" | ","alterations":" MYD88 L265P","tags":["MYD88"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MYD88 L265P"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e bazlitoran (IMO-8400)"],"overall_status":"Completed","enrollment":" Enrollment 6","initiation":"Initiation: 06/01/2014","start_date":" 06/01/2014","primary_txt":" Primary completion: 12/01/2016","primary_completion_date":" 12/01/2016","study_txt":" Completion: 12/01/2016","study_completion_date":" 12/01/2016","last_update_posted":"2017-12-12"}]